Companies Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals CEO salary & total pay, FY2022: $204K
Eiger BioPharmaceuticals (EIGR) CEO salary, fiscal 2022: David Apelian was paid a salary of $30,875 and $204,386 in total compensation. Free brief. Every figure links to the company’s own filing.
Eiger BioPharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2022.
David Apelian's complete compensation dossier
A PDF and a CSV sent to your email: David Apelian's pay in every fiscal year Eiger BioPharmaceuticals, Inc. reported it, line by line, with David Apelian's equity grants and Eiger BioPharmaceuticals, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $3,504,020FY2021
- $204,386FY2022
CEO total pay was $204,386 in fiscal 2022 (David Apelian), down from $3,504,020 in fiscal 2021 (David Cory, the CEO that year).
FY2022: salary $30,875 · bonus $0 · stock awards $0 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Cory | $649,106 | $0 | $239,700 | $895,884 | $376,200 | $0 | $1,522,971 | $3,683,861 |
| Former President and Chief Executive Officer | ||||||||
| Sriram Ryali | 500,000 | 0 | 122,400 | 455,913 | 200,000 | 0 | 13,633 | 1,291,946 |
| Former Chief Financial Officer | ||||||||
| Eldon Mayer | 410,000 | 0 | 81,600 | 312,444 | 172,200 | 0 | 4,763 | 981,007 |
| Executive Vice President and Chief Commercial Officer | ||||||||
| David Apelian | 30,875 | 0 | 0 | 0 | 0 | 0 | 173,511 | 204,386 |
| Interim Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| David Cory | $3,683,861 | $3,504,020 | — | ↑ +179,841 |
| Sriram Ryali | 1,291,946 | 2,050,365 | — | ↓ −758,419 |
| Eldon Mayer | 981,007 | 1,230,265 | — | ↓ −249,258 |
| David Apelian | 204,386 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation policies are designed to attract and retain talented and skilled executives by paying for performance and to align the compensation of executives with the interests of stockholders through a mix of short-term and long-term compensation. Equity grants are utilized to create an ownership culture and align executive interests with stockholders, while time-based vesting features promote executive retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Apelian | OPTION | 2022-03-11 | — | — | 12,000 | — | — |
| David Cory | OPTION | 2022-03-11 | — | — | 263,436 | — | — |
| Eldon Mayer | OPTION | 2022-03-11 | — | — | 17,011 | — | — |
| Eldon Mayer | OPTION | 2022-03-11 | — | — | 80,989 | — | — |
| Sriram Ryali | OPTION | 2022-03-11 | — | — | 134,061 | — | — |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| David Apelian | Option | 2,460 | 6,907 | 14.31 | — |
| David Apelian | Option | 9,000 | 3,000 | 5.1 | — |
| David Apelian | RSU | — | 6,000 | — | 7,080 |
| David Apelian | Option | 25,000 | — | 10.75 | — |
| David Apelian | Option | 25,022 | — | 13.7 | — |
| David Apelian | Option | 124,978 | — | 13.7 | — |
| David Apelian | Option | 27,750 | — | 9.5 | — |
| David Apelian | Option | 9,250 | — | 9.5 | — |
| David Apelian | Option | 101,133 | — | 14.31 | — |
| David Apelian | Option | 10,000 | — | 5.6 | — |
| David Apelian | Option | 10,000 | — | 9.99 | — |
| David Cory | Option | — | 6,988 | 14.31 | — |
| David Cory | Option | 187,500 | 5,512 | 14.31 | — |
| David Cory | Option | — | 14,375 | 5.6 | — |
| David Cory | Option | 158,125 | 57,500 | 5.6 | — |
| David Cory | Option | — | 11,961 | 9.99 | — |
| David Cory | Option | 122,937 | 146,102 | 9.99 | — |
| David Cory | RSU | — | 31,333 | — | 36,973 |
| David Cory | Option | 23,020 | 25,730 | 8.15 | — |
| David Cory | PSU | — | 30,000 | — | 35,400 |
| David Cory | RSU | — | 47,000 | — | 55,460 |
| David Cory | Option | — | 17,564 | 5.1 | — |
| David Cory | Option | 52,687 | 210,749 | 5.1 | — |
| David Cory | Option | 17,504 | — | 1.38 | — |
| David Cory | Option | 56,889 | — | 1.38 | — |
| David Cory | Option | 74,393 | — | 2.06 | — |
| David Cory | Option | 261,437 | — | 15.89 | — |
| David Cory | Option | 24,554 | — | 15.89 | — |
| David Cory | Option | 8,313 | — | 11.75 | — |
| David Cory | Option | 124,687 | — | 11.75 | — |
| David Cory | Option | 10,770 | — | 9.5 | — |
| David Cory | Option | 179,230 | — | 9.5 | — |
| Eldon Mayer | Option | 66,184 | 25,993 | 12.36 | — |
| Eldon Mayer | Option | 11,257 | 9,811 | 12.36 | — |
| Eldon Mayer | Option | 31,171 | 29,482 | 9.99 | — |
| Eldon Mayer | Option | — | 10,597 | 9.99 | — |
| Eldon Mayer | RSU | — | 7,916 | — | 9,341 |
| Eldon Mayer | Option | 8,263 | 9,237 | 8.15 | — |
| Eldon Mayer | PSU | — | 30,000 | — | 35,400 |
| Eldon Mayer | RSU | — | 16,000 | — | 18,880 |
| Eldon Mayer | Option | 1 | 17,010 | 5.1 | — |
| Eldon Mayer | Option | 18,374 | 62,615 | 5.1 | — |
| Eldon Mayer | Option | 12,492 | — | 13.7 | — |
| Eldon Mayer | Option | 4,996 | — | 9.5 | — |
| Eldon Mayer | Option | 4,996 | — | 14.31 | — |
| Sriram Ryali | Option | — | 20,313 | 5.6 | — |
| Sriram Ryali | Option | 42,656 | 40,118 | 9.99 | — |
| Sriram Ryali | Option | — | 14,726 | 9.99 | — |
| Sriram Ryali | RSU | — | 10,833 | — | 12,783 |
| Sriram Ryali | Option | — | 4,608 | 8.49 | — |
| Sriram Ryali | Option | 34,437 | 47,955 | 8.49 | — |
| Sriram Ryali | Option | 14,166 | 15,834 | 8.15 | — |
| Sriram Ryali | PSU | — | 30,000 | — | 35,400 |
| Sriram Ryali | RSU | — | 24,000 | — | 28,320 |
| Sriram Ryali | Option | — | 8,939 | 5.1 | — |
| Sriram Ryali | Option | 26,812 | 107,249 | 5.1 | — |
| Sriram Ryali | Option | 38,240 | — | 10.46 | — |
| Sriram Ryali | Option | 51,760 | — | 10.46 | — |
| Sriram Ryali | Option | 44,687 | — | 5.6 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas Dietz, Ph.DIndependent · Board Chair · Compensation · Nominating and Governance · Audit (Chair) | $170,000 | $30,600 | $73,980 | — | — | $274,580 |
| Lisa Kelly-CroswellIndependent · Nominating and Governance · Newly elected | 22,500 | 0 | 158,568 | — | — | 181,068 |
| Evan Loh, M.DIndependent · Compensation (Chair) · Nominating and Governance | 69,500 | 30,600 | 36,990 | — | — | 137,090 |
| Amit K. Sachdev, J.DIndependent · Compensation · Nominating and Governance (Chair) | 67,500 | 30,600 | 36,990 | — | — | 135,090 |
| Jeffrey Glenn, M.D., Ph.DIndependent · Audit · Compensation | 67,000 | 30,600 | 36,990 | — | — | 134,590 |
| Christine Murray, M.S., R.A.CIndependent · Audit · Nominating/Governance | 64,500 | 30,600 | 36,990 | — | — | 132,090 |
| Kim Sablich, M.B.AIndependent · Audit | 57,000 | 30,600 | 36,990 | — | — | 124,590 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 22,500 / 17,000 / 12,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $518,000 |
| Equity awards (grant-date value) | $183,600 |
| All other compensation | $0 |
| Total cost of the board | $701,600 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Eiger BioPharmaceuticals as a peer
Companies that benchmark against EIGR
The list of companies that name EIGR as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eiger BioPharmaceuticals, Inc. | 2022 | David Apelian | $30,875 | $0 | $0 | $0 | $204,386 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-15 | 9,827,476 | 15,512,014 | 43,822 | 38.72% | Failed |
| 2022 | 2022-06-16 | 16,752,944 | 9,086,605 | 333,718 | 64.01% | Passed |
| 2021 | 2021-06-14 | 19,555,119 | 773,615 | 199,598 | 95.26% | Passed |
| 2020 | 2020-06-15 | 15,873,661 | 285,634 | 151,070 | 97.32% | Passed |
| 2019 | 2019-06-11 | — | — | — | — | — |
| 2018 | 2018-06-12 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2023 | 2023-06-15 | 38.72%a |
| 2022 | 2022-06-16 | 64.01%b |
| 2021 | 2021-06-14 | 95.26%c |
a. Approved under the standard stated in the filing — “Approval on an advisory basis of the compensation of the Company's named executive officers -- "For" votes from the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the matter | Abstentions: Against”.
b. Approved under the standard stated in the filing — “Approval on an advisory basis of the compensation of the Company's named executive officers -- "For" votes from the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the matter | Abstentions: Against”.
c. Approved under the standard stated in the filing — “Approval on an advisory basis of the compensation of the Company's named executive officers -- "For" votes from the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the matter | Abstentions: Against”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James Vollins | General Counsel | 2023-04-30 | A | 120,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| David Apelian | Director | 2023-07-03 | A | 750,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ingrid Choong | Chief Business Officer | 2023-08-31 | A | 54,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leen Kawas | Greater-than-10% holder | 2023-10-31 | A | 12,345 | 0 | 3,228 | Common, indirect | Form 4 ↗ |
| Leen Kawas | Greater-than-10% holder | 2023-10-31 | A | 11,987 | 0 | 3,147 | Common, indirect | Form 4 ↗ |
| Richard A. Kayne | Greater-than-10% holder | 2023-10-31 | A | 130,509 | 0 | 31,505 | Common, indirect | Form 4 ↗ |
| Richard A. Kayne | Greater-than-10% holder | 2023-10-31 | A | 12,345 | 0 | 3,228 | Common, indirect | Form 4 ↗ |
| Richard A. Kayne | Greater-than-10% holder | 2023-10-31 | A | 11,987 | 0 | 3,147 | Common, indirect | Form 4 ↗ |
| Richard A. Kayne | Greater-than-10% holder | 2023-11-01 | A | 100,000 | 0 | 27,970 | Common, indirect | Form 4 ↗ |
| Richard A. Kayne | Greater-than-10% holder | 2023-11-02 | A | 23,398 | 0 | 6,966 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (32 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Cory. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 3,683,861. View filing ↗
- Section 01, Sriram Ryali. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 1,291,946. View filing ↗
- Section 01, Eldon Mayer. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 981,007. View filing ↗
- Section 01, David Apelian. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 204,386. View filing ↗
- Section 03, David Apelian OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, David Cory OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Eldon Mayer OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Eldon Mayer OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sriram Ryali OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Thomas Dietz, Ph.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 274,580. View filing ↗
- Section 08, Lisa Kelly-Croswell. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 181,068. View filing ↗
- Section 08, Evan Loh, M.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 137,090. View filing ↗
- Section 08, Amit K. Sachdev, J.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 135,090. View filing ↗
- Section 08, Jeffrey Glenn, M.D., Ph.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 134,590. View filing ↗
- Section 08, Christine Murray, M.S., R.A.C. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 132,090. View filing ↗
- Section 08, Kim Sablich, M.B.A. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 124,590. View filing ↗
- Section 02, James Vollins 2023-04-30. Form 4, filed 2023-05-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Apelian 2023-07-03. Form 4, filed 2023-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ingrid Choong 2023-08-31. Form 4, filed 2023-09-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leen Kawas 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leen Kawas 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Kayne 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Kayne 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Kayne 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Kayne 2023-11-01. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Kayne 2023-11-02. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-20. Item 5.07 · say-on-pay result. As reported: 38.72% (votes for as printed: 9,827,476). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-21. Item 5.07 · say-on-pay result. As reported: 64.01% (votes for as printed: 16,752,944). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-06-15. Item 5.07 · say-on-pay result. As reported: 95.26% (votes for as printed: 19,555,119). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 518,000 + equity 183,600 + all other 0 = 701,600, summed across the director compensation table rows.
- Eiger BioPharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-04-26. CEO total compensation as printed in Eiger BioPharmaceuticals, Inc.'s own proxy. As printed: 204,386. View filing ↗